Cart
sales@molnova.com
Evobrutinib
CAS No. 1415823-73-2
Evobrutinib( M2951 | MSC2364447C | MSC 2364447 )
Catalog No. M11730 CAS No. 1415823-73-2
A potent, highly selective BTK inhibitor for the treatment of various autoimmune disorders.Rheumatoid ArthritisPhase 2 Clinical
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 85 | In Stock |
|
| 5MG | 77 | In Stock |
|
| 10MG | 123 | In Stock |
|
| 25MG | 227 | In Stock |
|
| 50MG | 323 | In Stock |
|
| 100MG | 461 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 995 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameEvobrutinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, highly selective BTK inhibitor for the treatment of various autoimmune disorders.Rheumatoid ArthritisPhase 2 Clinical
-
DescriptionA potent, highly selective BTK inhibitor for the treatment of various autoimmune disorders.Rheumatoid Arthritis Phase 2 Clinical.
-
In Vitro——
-
In Vivo——
-
SynonymsM2951 | MSC2364447C | MSC 2364447
-
PathwayTyrosine Kinase
-
TargetBTK
-
RecptorBTK
-
Research AreaInflammation/Immunology
-
IndicationRheumatoid Arthritis
Chemical Information
-
CAS Number1415823-73-2
-
Formula Weight429.51418
-
Molecular FormulaC25H27N5O2
-
Purity>98% (HPLC)
-
SolubilityDMSO: 6.4 mg/mL (Need ultrasonic)
-
SMILESC=CC(N1CCC(CNC2=NC=NC(N)=C2C3=CC=C(OC4=CC=CC=C4)C=C3)CC1)=O
-
Chemical Name2-Propen-1-one, 1-[4-[[[6-amino-5-(4-phenoxyphenyl)-4-pyrimidinyl]amino]methyl]-1-piperidinyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Patent US20140162983 example 0174.
molnova catalog
related products
-
NX-2127
NX-2127 (ETX2514 Triethylamine) is an orally active BTK inhibitor that induces degradation of mutant BTKC481S in cells.NX-2127 has potent antiproliferative activity and inhibits the proliferation of BTKC481S mutant TMD8 cells.
-
BTK inhibitor 17
BTK inhibitor 17 is a potent irreversible BTK inhibitor (IC50 = 2.1 nM). BTK inhibitor 17 can be used in rheumatoid arthritis studies.
-
MDVN-1003
A first-in-class, selective, orally bioavailable, dual inhibitor of BTK and PI3Kδ kinases with IC50 of 32.3 nM and 16.9 nM, respectively.
